

Claudia Wild



Member of the IHI JU Science and Innovation Panel

CEO / Scientific Director of HTA Austria, Austrian Institute for Health Technology Assessment

Claudia Wild (CW) is Chief Executive Officer (CEO) of AIHTA GesmbH since 2020.

Before she has been Director of the Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) since its establishment in 2006. From 1989-2006 CW worked as a Senior Researcher at the Institute of Technology Assessment (ITA) at the Austrian Academy of Sciences and developed the research field HTA in Austria. Prior to that, CW conducted research on "media impact on cognitions" at the Institute for Communications and Political Science at the University of Nürnberg/ Germany.

CW studied communications & psychology at the University of Vienna and political sciences at the Ohio University/USA and completed her studies with a Graduation at the University of Vienna as Doctor of Philosophy in 1985. In 2009, she habilitated in social medicine (Medical University Graz) on the topic of "resource allocation in health-care systems".

The AIHTA is engaged in numerous EC-projects and initiatives, such as EUnetHTA, Core-MD, AdHopHTA, etc.

Advisory Activities (excerpt):

Since 2021 member of Joint Access Advisory Mechanism (JAAM) for covid-19 platform trials

Since 2020 member in EXPAMED (EC-Expert panels on medical devices and in vitro diagnostic medical devices)

From 2017 to 2019 member of the EC-Expert Panel on "Effective Ways of Investing in Health"

Since 2011 member of the National Oncology Advisory Board for developing a national cancer plan

Since 2007 member of the working group "Public Health" at Transparency International – Austrian Chapter